Brainomix said its e-Lung software detects lung scarring and may help with earlier diagnosis and more accurate monitoring of ...

Long-term treatment with deupirfenidone (LYT-100) is generally well tolerated and may stabilize lung function in people with ...

For the first time in more than 10 years, idiopathic pulmonary fibrosis (IPF) care teams and patients will have a new treatment option following the Oct. 7 approval of Jascayd (nerandomilast) by the U ...

Guest writer Kylene Henderson recalls the lengthy journey she and her husband faced to get answers and a pulmonary fibrosis diagnosis.

Columnist Sam Kirton shares his thoughts on recent CDC vaccine recommendations, as well as his experience before and after transplant.

An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical trial, according to interim data announced by its developer GRI Bio. “We are ...

The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat adults with idiopathic pulmonary fibrosis (IPF) — when the lung ...

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

There is no cure for pulmonary fibrosis (PF), but many therapies are in the pipeline that may be able to slow disease progression, manage symptoms, and improve quality of life for patients. Some of ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

The U.S. Food and Drug Administration (FDA) has granted its orphan drug designation to Alentis Therapeutics’ antibody-based therapy lixudebart (ALE.F02) for idiopathic pulmonary fibrosis (IPF). Orphan ...